Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
HE R2 receptor inhibition
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:China
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:developed_by |
Qilu Pharmaceutical
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab-qyyp
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:marketed_as |
Qyyp
|
| gptkbp:targets |
HE R2
|
| gptkbp:type |
gptkb:physicist
|
| gptkbp:bfsParent |
gptkb:trastuzumab
|
| gptkbp:bfsLayer |
5
|